Major Pharma Company Announces $2B Acquisition in Rare Disease Space
Deal marks the largest acquisition in the rare disease sector this year, expanding portfolio significantly.
Stay updated with the latest news in pharma and healthcare
Deal marks the largest acquisition in the rare disease sector this year, expanding portfolio significantly.
First-of-its-kind treatment offers potential cure for patients with severe sickle cell disease.
Funding will accelerate clinical trials for novel CAR-T cell therapy targeting solid tumors.
Phase 3 data reveals significant cognitive improvement in early-stage patients over 18 months.
Partnership aims to deploy AI-powered diagnostic tools across 200+ facilities nationwide.
Research reveals potential therapeutic targets for treating depression and anxiety disorders.
Policy change will provide access to CGM devices for millions of diabetes patients.
New facility will increase global production capacity for next-generation vaccines.
Growth driven by aging population and increased adoption of telehealth services.